Webinar: Immunomonitoring with TCR sequencing for T1D drug development

Type 1 diabetes is driven by T cells attacking insulin-producing beta cells in the pancreas. Yet most clinical trials in T1D still rely on metabolic endpoints, potentially missing important immune signals.

TCR sequencing gives you direct access to the T cell response. This webinar shows you how to turn that data into actionable immune signals for T1D drug development: tracking antigen-specific T cell populations, detecting repertoire shifts under treatment, and identifying biomarkers that correlate with clinical outcomes.

You will learn:

• How to design an immunomonitoring strategy around TCR sequencing for T1D trials
• How DETECT predicts TCR epitope specificity (including a set of T1D-relevant antigens)
• Bringing this all together on a T1D use case

This session is for clinical scientists, translational researchers, and biomarker leads at pharma and biotech companies working on T1D therapies.

Two time slots on 29 July 2026: 16:00-17:00 CEST and 20:00-21:00 CEST.